FIELD: Revolutionizing Canine Lung Cancer Treatment

The Need: Lung cancer in canines poses significant clinical challenges, mirroring the complexities of human lung cancer in non-smokers. With limited standard treatments beyond surgery, there's an urgent demand for advanced methods to assess, characterize, diagnose, and treat these cancers effectively. Additionally, there's a critical need for enhanced biological understanding and translational research models to drive progress in never-smoker lung cancer treatment.

The Technology: Our innovative technology provides comprehensive methods for assessing, characterizing, diagnosing, and treating lung cancer in canines, particularly focusing on pulmonary adenocarcinomas, adenosquamous, and squamous cell carcinomas. By analyzing biological samples, such as tumor or plasma samples, our approach enables precise detection of mutations associated with canine lung cancer, including HER2 V659E, A664T, and K676E, among others. Leveraging advanced sequencing techniques and targeted therapies, such as HER2 inhibitors like trastuzumab and neratinib, our technology offers personalized treatment strategies tailored to individual canine patients.

Commercial Applications:

• Veterinary oncology clinics: Implementing advanced diagnostics and targeted therapies for improved management of canine lung cancer.
• Pharmaceutical companies: Research and development of canine-specific cancer treatments, leveraging our technology for preclinical studies.
• Biotechnology firms: Utilizing our methods for comparative oncology research to gain insights applicable to human lung cancer treatment.

Benefits/Advantages:

• Precision medicine for canines: Tailored treatment approaches based on individual cancer characteristics, leading to enhanced efficacy and reduced side effects.
• Accelerated drug development: Facilitating the identification and validation of potential therapeutic targets through comprehensive molecular profiling of canine lung cancer.
• Improved patient outcomes: Early detection of actionable mutations and targeted therapy selection contribute to prolonged survival and enhanced quality of life for canine patients.